Most of applicable respondents’ companies developed their most advanced program in house, while the proportion of companies licensing in their most advanced programs was slightly higher than 20% in 2019.
Most applicable respondents who were comfortable enough to disclose their companies’ activities named an even selection of different CMOs and CROs. However, Nitto Avecia was the highest named, with Bachem and Biospring closely behind.
Just less than half of respondents described their partnering and licensing as having increased since the start of the COVID-19 pandemic, while the vast majority of others said that these activities had stayed about the same for their organization.
The majority of respondents working in biotech companies, service providers and investment said that activities had increased, while most of those working in consultancies said that their company’s partnering and licensing had decreased, and most of respondents working academic institutions said that these activities were about the same since the pandemic began.
In the additional comments, some respondents reported that entering into new products created an increase in partnering activities within their organization. Some also expressed that limited access to labs and academic research during lockdown has forced their companies to look into new strategies to carry out their research.
